Late manifestation of autoimmune polyglandular syndrome type 1 with hypoparathyroidism and autoimmune thyroiditis

Autoimmune polyglandular syndrome type 1 (APS 1) is a rare genetic disorder caused by a mutation in the autoimmune regulator AIRE gene. The diagnosis is usually based on the combination of at least two components of the classic triad: mucocutaneous candidiasis, hypoparathyroidism, and primary adrenal insufficiency. Other autoimmune disorders, including thyroid diseases, also occur and may manifest before the primary components. The disease is more likely to   manifest during infancy, but some components may develop in adult patients. As the components of the syndrome do not occur simultaneously, verification of the diagnosis is often delayed. A significant challenge in the management of patients with APS 1 is the selection of optimal drug doses due to polypragmasy and the frequent presence of autoimmune disorders and/or candidiasis of the gastrointestinal tract. We present a clinical case of a patient with an atypical course of APS 1, in whom the first endocrine components (hypoparathyroidism and hypothyroidism) were diagnosed in adulthood. This case highlights the phenotypic diversity of APS 1, and the difficulties in selecting therapy when several autoimmune endocrine diseases are combined.

1. Michels AW, Gottlieb PA. Autoimmune polyglandular syndromes. Nature Reviews Endocrinology. 2010;6(5):270-277. doi: https://doi.org/10.1038/nrendo.2010.40

2. Lima Ferreira J, Simões de Carvalho F, Marques AP, et al. Hypoparathyroidism as the single major component for decades of autoimmune polyglandular syndrome type 1. Endocrinol Diabetes Metab Case Rep. 2021;2020. doi: https://doi.org/10.1530/edm-20-0083

3. Bjorklund G, Pivin M, Hangan T, et al. Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach. Autoimmunity Reviews, vol. 21, no. 8. Elsevier B.V., 2022. doi: https://doi.org/10.1016/j.autrev.2022.103135

4. Garelli S et al. Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients. J Endocrinol Invest. 2021;44(11):2493-2510. doi: https://doi.org/10.1007/s40618-021-01585-6

5. Ahonen P, Myllärniemi S, Sipilä I, et al. Clinical Variation of Autoimmune Polyendocrinopathy–Candidiasis–Ectodermal Dystrophy (APECED) in a Series of 68 Patients. N Engl J Med. 1990;322(26):1829-1836. doi: https://doi.org/10.1056/NEJM199006283222601

6. Cetani F, Barbesino G, Borsari S, et al. A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly cosegregating with hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab. 2001;86(10):4747-52. doi: https://doi.org/10.1210/jcem.86.10.7884

7. Orlova E.M. et al. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism. 2017;102(9):3546-3556. doi: https://doi.org/10.1210/jc.2017-00139

8. Homik J, Suarez-Almazor M.E, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews, 1998. doi: https://doi.org/10.1002/14651858.cd000952

9. Mazziotti G, Formenti AM, Frara S, et al. Vitamin D and Glucocorticoid-Induced Osteoporosis. Front Horm Res. 2018;50:149-160. doi: https://doi.org/10.1159/000486078

10. Singh N, Singh PN, Hershman JM. Effect of Calcium Carbonate on the Absorption of Levothyroxine. [Online]. Available: https://jamanetwork.com/

11. Wang YB, et al, Characterization of the clinical and genetic spectrum of autoimmune polyendocrine syndrome type 1 in Chinese case series. Orphanet J Rare Dis. 2021;16(1). doi: https://doi.org/10.1186/s13023-021-01933-y

12. Savvateeva EN, Yukina MY, Nuralieva NF, et al. Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes. International Journal of Molecular Sciences Article J. Mol. Sci, 2021. doi: https://doi.org/10.3390/ijms